Genetic abnormality | Clinical entity* | Rearrangement | Junctions‡ |
|---|
TCF3-PBX1 | Pre-B/B-ALL | t(1;19)(q23;p13.3) | 60 |
BCR-ABL1 | CML | t(9;22)(q34;q11) | 67 |
t-MLL | Therapy AML | t(9;11)(q22;q23) | 26 |
MLL | Primary ALL and AML | t(4;11)(q21;q23) | 424 |
| | | t(9;11)(q22;q23) | 24 |
ETV6-RUNX1 | Pre-B/B-ALL | t(12;21)(p12;q22) | 105 |
RUNX1-RUNX1T1 | AML | t(8;21)(q22;q22) | 132 |
MYC-IGH | Sporadic BL | t(8;14)(q24;q32) | 178 |
BCL6-IGH | Mature B lymphomas | t(3;14)(q27;q32) | 52 |
SCL-TCRA | Pre-T/T ALL | t(1;14)(q32;q11) | 48 |
LMO2-TCRA | Pre-T/T ALL | t(11;14)(q13;q11) | 58 |
Total | | | 1174 |
- TCF3: transcription factor 3; PBX1: pre B-cell leukemia transcription factor 1; BCR: breakpoint cluster region; ABL1: Abelson murine leukemia viral oncogene homolog 1; MLL: myeloid/lymphoid or mixed lineage leukemia gene; ETV6: ets variant gene 6; RUNX1: runt-related transcription factor 1; RUNX1T1: runt-related transcription factor 1 translocated to, 1; MYC: v-myc avian myelocytomatosis viral oncogene homolog; IGH: IgG heavy chain locus; BCL6: B-cell lymphoma 6; SCL: stem cell leukemia hematopoietic transcription factor; TCRA: T-cell antigen receptor, alpha subunit; LMO2: lim domain only 2, t: therapy related.
- *Distinct hematolymphoid neoplasms according to the World Health Organization classification; Pre-B/B-ALL: B lymphoblastic leukemia/lymphoma; CML: chronic myelogenous leukemia; Therapy AML: therapy-related acute myeloid leukemia; sporadic BL: Burkitt lymphoma; Pre-T/T-ALL: T lymphoblastic leukemia/lymphoma.
- ‡Number of translocation junctions examined.
